Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
A new study published in the Journal of American Medical Association showed that veterans, 60 years of age and older who got ...
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...
Shots to prevent respiratory syncytial virus recommended only for high-risk babies even as experts hail jabs’ success ...
A vaccine developed to tackle Streptococcus suis, an economically damaging disease endemic in the global pig population, has ...
Clover Biopharmaceuticals begins phase 2 trial for RSV + hMPV ± PIV3 respiratory combination vaccine candidates: Shanghai Tuesday, January 13, 2026, 17:00 Hrs [IST] Clover Biopha ...
MedPage Today on MSN
Interim safety data reassure on RSV vaccine in pregnant women
No statistically significant differences in preterm birth, hypertensive disorders of pregn ...
Robert F. Kennedy, Jr.’s Centers for Disease Control and Prevention has slashed childhood vaccine recommendations in the ...
Amid a worsening respiratory illness season, the Centers for Disease Control and Prevention recently rolled back its ...
Health and Me on MSNOpinion
RSV vaccine has benefits, reveals study amid CDC's changed guidelines on childhood vaccines
RSV is a leading cause of infant hospitalizations, but prevention shots approved in 2023 have sharply reduced severe illness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results